Non-tuberculous mycobacteria pulmonary infection:: Management and follow-up of 31 infected patients

被引:22
作者
Andrejak, Claire [1 ]
Lescure, Francois-Xavier
Douadi, Youcef
Laurans, Genevieve
Smail, Amar
Duhaut, Pierre
Jounieaux, Vincent
Schmit, Jean-Luc
机构
[1] Univ Hosp, Dept Pneumol, F-80054 Amiens 1, France
[2] Univ Hosp, Infect Dis & Internal Med Dept, Amiens, France
[3] Tenon Univ Hosp AP HP, Dept Infect Dis, Paris, France
[4] Univ Hosp, Dept Bacteriol, Amiens, France
关键词
mycobacterial; pulmonary; infections; antibiotics;
D O I
10.1016/j.jinf.2007.01.008
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: The global number of non-tuberculous mycobacteria (NTM) pulmonary infections is increasing. Treatment decisions and management are difficult and the prognosis of these infections has been rarely evaluated. Methods: The aim of this study was to evaluate management and prognosis of patients with NTM pulmonary infection in a French teaching hospital. In this study, we evaluated management of patients satisfying the ATS (American Thoracic Society) criteria for NTM pulmonary infection in Amiens hospital from 1992 to 2002 and retrospectively compared this management to ATS guidelines. Short-term and long-term survival was also described. Results: Thirty-one patients satisfying the ATS criteria for NTM pulmonary infection were included: 15 patients were infected with Mycobacterium xenopi, nine with Mycobacterium avium intracellulare, four with Mycobacterium kansasii and three patients were infected with rapidly growing mycobacteria. Twenty-seven patients had past or concomitant diseases responsible for Local or systemic immunosuppression. Eleven patients were not treated. In the 20 treated patients, 13 different antibiotic combinations were used, often comprising three or more drugs. The median survival was 15 months. Twenty-one patients (67%) died before 5 years of follow-up. Thirty per cent of deaths were attributed to NTM pulmonary infection. Adjusting treatment to the results of susceptibility tests or ATS guidelines was not associated with any significant difference in survival. Conclusion: As the high mortality rate may be related to concomitant diseases, management of NTM pulmonary infection also depends on comorbidities, and should be defined according to the severity of underlying diseases. (c) 2007 The British Infection Society. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:34 / 40
页数:7
相关论文
共 26 条
[1]  
Campbell I, 2000, THORAX, V55, P210
[2]   CLARITHROMYCIN THERAPY FOR BACTEREMIC MYCOBACTERIUM-AVIUM COMPLEX DISEASE - A RANDOMIZED, DOUBLE-BLIND, DOSE-RANGING STUDY IN PATIENTS WITH AIDS [J].
CHAISSON, RE ;
BENSON, CA ;
DUBE, MP ;
HEIFETS, LB ;
KORVICK, JA ;
ELKIN, S ;
SMITH, T ;
CRAFT, JC ;
SATTLER, FR ;
STOOL, EW ;
MACGREGOR, RR ;
BUEHNER, T ;
WU, AW ;
BARNES, GL ;
BECKER, R ;
URBANSKI, P ;
RICHARDSON, W ;
HAFNER, R ;
DIXON, D ;
FEIGAL, DW ;
DELLERSON, M ;
GUPTA, S ;
HENRY, D ;
SCHLAGER, S .
ANNALS OF INTERNAL MEDICINE, 1994, 121 (12) :905-911
[3]   Nontuberculous mycobacteria in women, young and old [J].
Chalermskulrat, W ;
Gilbey, JG ;
Donohue, JF .
CLINICS IN CHEST MEDICINE, 2002, 23 (03) :675-+
[4]   Treatment of refractory disseminated Mycobacterium abscessus infection with interferon gamma therapy [J].
Colsky, AS ;
Hanly, A ;
Elgart, G ;
Kerdel, FA .
ARCHIVES OF DERMATOLOGY, 1999, 135 (02) :125-127
[5]   Pulmonary disease caused by rapidly growing mycobacteria [J].
Daley, CL ;
Griffith, DE .
CLINICS IN CHEST MEDICINE, 2002, 23 (03) :623-+
[6]   CLARITHROMYCIN IN THE TREATMENT OF MYCOBACTERIUM-AVIUM LUNG INFECTIONS IN PATIENTS WITHOUT AIDS [J].
DAUTZENBERG, B ;
PIPERNO, D ;
DIOT, P ;
TRUFFOTPERNOT, C ;
CHAUVIN, JP .
CHEST, 1995, 107 (04) :1035-1040
[7]   In vitro susceptibilities of rapidly growing mycobacteria to telithromycin (HMR 3647) and seven other antimicrobials [J].
Fernández-Roblas, R ;
Esteban, J ;
Cabria, F ;
López, JC ;
Jiménez, MS ;
Soriano, F .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (01) :181-182
[8]   Nontuberculous mycobacteria in non-HIV patients: epidemiology, treatment and response [J].
Henry, MT ;
Inamdar, L ;
O'Riordain, D ;
Schweiger, M ;
Watson, JP .
EUROPEAN RESPIRATORY JOURNAL, 2004, 23 (05) :741-746
[9]   Medical management of pulmonary disease caused by Mycobacterium avium complex [J].
Iseman, MD .
CLINICS IN CHEST MEDICINE, 2002, 23 (03) :633-+
[10]   Pulmonary disease caused by Mycobacterium xenopi in HIV-negative patients:: five year follow-up of patients receiving standardised treatment [J].
Jenkins, PA ;
Campbell, IA .
RESPIRATORY MEDICINE, 2003, 97 (04) :439-444